Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Name: Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
License: Public Domain

M.D. Anderson Cancer Center

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

allogeneic hematopoietic stem cell transplantation recipient, myelodysplastic syndrome, recurrent acute myeloid leukemia, refractory acute myeloid leukemia

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 405138
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.